Cyclodextrin-based nanosponges as vehicles for antiviral drugs: challenges and perspectives

• Published in: Nanomedicine (London, England) Vol. 13; no. 5; pp. 477 - 480
• Main Authors: Lembo, David, Trotta, Francesco, Cavalli, Roberta
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.03.2018
• Subjects: Antiviral Agents - administration & dosage; Antiviral Agents - chemistry; antiviral drugs; beta-Cyclodextrins - chemistry; Bioavailability; Cancer therapies; Drug Carriers - chemistry; Drug dosages; Drug Liberation; HIV; Human immunodeficiency virus; Humans; Molecular Targeted Therapy; Nanoparticles; Nanoparticles - chemistry; nanosponges; Pharmaceuticals; Polymers; Solubility; Tissue Distribution; Viral infections; Virus Diseases - drug therapy; Viruses; β-cyclodextrins; antiviral drugs; nanosponges; β-cyclodextrins; viral infections
• ISSN: 1743-5889; 1748-6963
• DOI: 10.2217/nnm-2017-0383

The reaction can be optimized to produce nanoparticles with specific chemical structure, sizes and surface charges. [...]stimuli-responsive nanosponges with a precise capacity to control drug release in response of external environmental changes have been designed (10,11). Torneetal. showed that the oral bioavailability of paclitaxel was increased about threefold after the oral administration of paclitaxel-loaded βCD-NS to rats, in comparison to the control (commercially available TAXOL® , Bristol-Myers Squibb Company, Chester, UK) (14). [...]efavirenz, a non-nucleoside reverse transcriptase inhibitor with a low aqueous solubility, was loaded in βCD-NS with the same aim. The local and specific release of antiviral drugs can decrease the administered doses and minimize damage to healthy cells. Besides small molecules, the use of silencing RNAs is an alternative antiviral strategy (19).